NICE recently issued a Final Appraisal Determination recommending vedolizumab (with PAS discount) as an option for treating moderate to severely active Crohn’s disease if an anti-TNF has failed (disease has responded inadequately or has lost response to treatment) or cannot be tolerated or is contra-indicated. Please see the link below for details.